Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.

Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study

Novartis AG said Monday that a trial to evaluate prostate-cancer drug Pluvicto met its primary endpoint in patients with a specific type of metastatic cancer.

Novartis prostate cancer drug trial meets primary endpoint

Ad hoc announcement pursuant to Art. 53 LR

Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

Novartis (NVS) Set to Advance Malaria Drug Into Phase III

Ardelyx

Merck

For investors looking for growth, biotech stocks are a great place to start one's search. This is a sector that's seen its valuation multiples decline in many cases to a greater extent than the overall market.

3 Biotech Stocks Smart Investors Should Be Buying Up Now

First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder.

Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.

Novartis (NVS) Reportedly Looking to Sell Its Business Units

We analyzed the latest Pharma conference with key takeaways on the Inflation Reduction Act development and the company's reorganization. Limited growth potential with no current positive catalyst.

Novartis: Limited Growth

Novartis' product portfolio and pipeline bode well for its future.

Should Income Investors Buy This High-Yielding Dividend Stock?

Enbridge

Verizon

These stocks are all trading close to their 52-week lows.

3 High-Yielding Dividend Stocks That You Can Buy and Hold Forever

Novartis AG (NYSE:NVS ) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Wimal Kapadia - Bernstein Richard Parkes - BNP Paribas Emmanuel Papadakis - Deutsche Bank Matthew Weston - Credit Suisse Simon Baker - Redburn Richard Wagner - Wolfe Research Stephen Scala - Cowen Kerry Holford - Berenberg Richard Vosser - JPMorgan Emily Field - Barclays Keyur Parekh - Goldman Sachs Mark Purcell - Morgan Stanley Seamus Fernandez - Guggenheim Securities Florent Cespedes - Societe Generale Andrew Baum - Citi Peter Welford - Jefferies Operator Good morning and good afternoon and welcome to the Novartis Q3 2022 Results Release Conference Call and Live Webcast. [Operator Instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.

Novartis AG (NVS) Q3 2022 Earnings Call Transcript

Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.

Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

Novartis reported revenues and earnings that were down year over year. Currency rate movements were responsible for that, however, Novartis' underlying performance was pretty solid.

Novartis: Healthy Results

Novartis stock was mostly unmoved Tuesday after the company's earnings beat expectations, but third-quarter sales came up short. The post Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff appeared first on Investor's Business Daily.

Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff

Vanguard Health Care ETF

Most investors, economists, CEOs, and the bond market are confident a recession is coming in 2023. That means potentially another 15% to 20% downside risk for the market. Consumer staples, healthcare, and utilities historically perform the best in recessions, but healthcare is the best performing defensive sector once the new bull market begins.

2 Dividend Blue-Chips Perfect For 2023

Amgen

AstraZeneca

IQVIA Hlds

Johnson & Johnson

Regeneron Pharmaceuticals

Biosimilars are bringing down prescription drug costs without sacrificing quality.

Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?

Novartis earnings and sales fall short of expectations, but backs 2022 view

Novartis maintains growth momentum and confirms FY'22 Group guidance

Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.

Novartis hemoglobinuria trial meets two primary endpoints

Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study

Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.

What's in Store for Novartis (NVS) This Earnings Season?

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.

Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

Basel, October 14, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617), a radioligand therapy, in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. “People at this advanced stage of disease have already received many different treatments and have few alternatives left,” said Prof. Karim Fizazi, MD, PhD, VISION trial investigator and Head of Medical Oncology at Gustave Roussy, first European cancer center based in Villejuif, France. “If approved in Europe, Pluvicto® would represent a new type of precision medicine targeting a biomarker broadly expressed in prostate cancer patients4 and provide a therapeutic option with demonstrated potential to improve outcomes1. As a clinician this gives me hope for patients facing a very difficult situation.”

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Paramount Global

Whether you're looking for dividends or growth, Novartis and Paramount Global could be viable options for you.

Got $5,000? These 2 Stocks Are Bargain Buys Right Now

Novartis recently announced encouraging results from its clinical trial of its Prolia biosimilar.

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

News for Novartis Stock (NVS)